Stay updated on Lecanemab Safety, Tolerability & Efficacy in Early Alzheimer's Clinical Trial
Sign up to get notified when there's something new on the Lecanemab Safety, Tolerability & Efficacy in Early Alzheimer's Clinical Trial page.

Latest updates to the Lecanemab Safety, Tolerability & Efficacy in Early Alzheimer's Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedMalmo, Sweden was removed and Malmö, Sweden was added in the Locations list, updating the Sweden entry to the correct local spelling.SummaryDifference0.0%

- Check18 days agoChange DetectedThe page footer’s software/version label was updated from “Revision: v3.5.0” to “Revision: v3.5.3,” indicating a platform release rather than a change to the underlying trial information.SummaryDifference0.0%

- Check54 days agoChange DetectedThe revision tag on the page was updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.0%

- Check69 days agoChange DetectedAdded official results data and expanded safety/efficacy endpoints for core and extension phases, including ADCOMS, CDR-SB, ADAS-Cog, CSF biomarkers, MRI volumetrics, and amyloid PET measures; TEAEs/SAEs definitions and the Results First Posted date are now included.SummaryDifference2%

- Check90 days agoChange DetectedRevision tag updated from v3.4.1 to v3.4.2 with no substantive content changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check98 days agoChange DetectedA new revision tag v3.4.1 was added and the previous v3.4.0 tag removed. No visible changes to core study content or functionality.SummaryDifference0.0%

Stay in the know with updates to Lecanemab Safety, Tolerability & Efficacy in Early Alzheimer's Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lecanemab Safety, Tolerability & Efficacy in Early Alzheimer's Clinical Trial page.